Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2021-10-19 Capital/Financing Update
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 15, 2021, reporting a material definitive agreement related to a securities purchase agreement and registration rights agreement. It details a private placement financing transaction including issuance of common stock and warrants, terms of the warrants, and registration rights. The document also includes information about compliance with a loan covenant and references exhibits containing the agreements. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising event and related agreements, which fits the category of Capital/Financing Update filings. The document length is over 13,000 characters, indicating it is not a brief announcement or a simple notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-10-19 English
S-3
Regulatory Filings Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing related to securities registration and offering. The document is lengthy (15,000 characters) and contains detailed registration information, prospectus summary, and legal disclosures. This type of filing is best classified under Regulatory Filings (RNS) as it does not fit into other specific categories like capital/financing update or proxy solicitation. Therefore, the appropriate classification is RNS with high confidence.
2021-10-15 English
RW
Regulatory Filings Classification · 95% confidence The document is a letter from Trevi Therapeutics, Inc. to the SEC requesting withdrawal of a Registration Statement on Form S-1 related to a proposed public offering. It explicitly states that the Registration Statement has not been declared effective and no securities were sold. The document is a formal regulatory communication about the withdrawal of a filing, not a financial report, earnings release, or other types of filings. It is short (2316 characters) and serves as a regulatory notice rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-10-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a securities purchase agreement involving a private placement of common stock and warrants, including details about the terms, registration rights, and related agreements. There are no financial statements or comprehensive financial performance data included. The document primarily announces a capital raising transaction and related agreements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed transaction information, not just a brief announcement or press release, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-10-01 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 for a securities offering by Trevi Therapeutics, Inc. The text includes details about the offering, company overview, risk factors, use of proceeds, underwriting, and other information typical of an S-1 filing. This type of document is related to capital raising and financing activities, specifically the registration of securities for public offering. Therefore, it fits the category of Capital/Financing Update filings.
2021-08-27 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.